Publications

• Long-Term Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor in Adults and Adolescents with Cystic Fibrosis and at Least One F508del Allele: A Phase 3, Open-Label Extension Study.
  Am J Respir Crit Care Med
  04/10/2025 Authors: Daines CL; Polineni D; Tullis E; Costa S; Linnemann RW; Mall MA; McKone EF; Quon BS; Ringshausen FC; Selvadurai H
• Vanzacaftor-tezacaftor-deutivacaftor versus elexacaftor-tezacaftor-ivacaftor in individuals with cystic fibrosis aged 12 years and older (SKYLINE Trials VX20-121-102 and VX20-121-103): results from two randomised, active-controlled, phase 3 trials.
  Lancet Respir Med Volume: 13 Page(s): 256 - 271
  03/01/2025 Authors: Keating C; Yonker LM; Vermeulen F; Prais D; Linnemann RW; Trimble A; Kotsimbos T; Mermis J; Braun AT; O'Carroll M
• Evaluation of elexacaftor-tezacaftor-ivacaftor treatment in individuals with cystic fibrosis and CFTRN1303K in the USA: a prospective, multicentre, open-label, single-arm trial.
  Lancet Respir Med Volume: 12 Page(s): 947 - 957
  12/01/2024 Authors: Solomon GM; Linnemann RW; Rich R; Streby A; Buehler B; Hunter E; Vijaykumar K; Hunt WR; Brewington JJ; Rab A
• Validation of the Integrated Palliative Care Outcome Scale (IPOS) in adults with cystic fibrosis.
  Pediatr Pulmonol Volume: 59 Page(s): 2857 - 2866
  11/01/2024 Authors: Georgiopoulos AM; DiFiglia S; Seng EK; Portenoy R; Chaudhary N; Wei R; Berdella MN; Friedman D; Kier C; Linnemann RW
• Impact of Discontinuing Both Hypertonic Saline and Dornase Alfa after Elexacaftor-Tezacaftor-Ivacaftor in Cystic Fibrosis.
  Ann Am Thorac Soc Volume: 21 Page(s): 1507 - 1515
  11/01/2024 Authors: Mayer-Hamblett N; Gifford AH; Kloster M; Russell R; Braun AT; Gibson RL; Hoppe JE; Jain R; Linnemann RW; Liou TG
• Interventions to improve system-level coproduction in the Cystic Fibrosis Learning Network.
  BMJ Open Qual Volume: 13
  07/27/2024 Authors: Gamel B; Albon D; Bandla S; Davison DW; Flath J; Sabadosa KA; Seid M; Silva L; Ong T; Cystic Fibrosis Learning Network Group
• Palliative care needs among outpatient adults with cystic fibrosis: Baseline data from the Improving Life with CF trial.
  J Cyst Fibros Volume: 23 Page(s): 804 - 810
  07/01/2024 Authors: DiFiglia S; Georgiopoulos AM; Portenoy R; Seng E; Berdella M; Friedman D; Kier C; Linnemann RW; Middour-Oxler B; Walker P
• Diagnostic challenges in CFTR-related metabolic syndrome: Where the guidelines fall short.
  Paediatr Respir Rev Volume: 49 Page(s): 28 - 33
  03/01/2024 Authors: Kallam EF; Kasi AS; Barr E; Linnemann RW; Guglani L
• Long-term safety and efficacy of elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis and at least one F508del allele: 144-week interim results from a 192-week open-label extension study.
  Eur Respir J Volume: 62
  12/01/2023 Authors: Daines CL; Tullis E; Costa S; Linnemann RW; Mall MA; McKone EF; Polineni D; Quon BS; Ringshausen FC; Rowe SM
• EFFECT OF ELEXACAFTOR/TEZACAFTOR/IVACAFTOR ON ANNUAL RATE OF LUNG FUNCTION DECLINE IN PEOPLE WITH CYSTIC FIBROSIS.
  J Cyst Fibros Volume: 22 Page(s): 402 - 406
  05/01/2023 Authors: Lee T; Sawicki GS; Altenburg J; Millar SJ; Geiger JM; Jennings MT; Lou Y; McGarry LJ; Van Brunt K; Linnemann RW
• Discontinuation versus continuation of hypertonic saline or dornase alfa in modulator treated people with cystic fibrosis (SIMPLIFY): results from two parallel, multicentre, open-label, randomised, controlled, non-inferiority trials.
  Lancet Respir Med Volume: 11 Page(s): 329 - 340
  04/01/2023 Authors: Mayer-Hamblett N; Ratjen F; Russell R; Donaldson SH; Riekert KA; Sawicki GS; Odem-Davis K; Young JK; Rosenbluth D; Taylor-Cousar JL
• Development of a Cystic Fibrosis Primary Palliative Care Intervention: Qualitative Analysis of Patient and Family Caregiver Preferences.
  J Patient Exp Volume: 10 Page(s): 23743735231161486
  01/01/2023 Authors: Basile MJ; Dhingra L; DiFiglia S; Polo J; Portenoy R; Wang J; Walker P; Middour-Oxler B; Linnemann RW; Kier C
• Cystic fibrosis learning network telehealth innovation lab during the COVID-19 pandemic: a success QI story for interdisciplinary care and agenda setting.
  BMJ Open Qual Volume: 11
  05/01/2022 Authors: Albon D; Thomas L; Hoberg L; Stamper S; Somerville L; Varghese P; Balasa E; Roman M; Britto MT; Miner M
• Serum anti-PAD4 autoantibodies are present in cystic fibrosis children and increase with age and lung disease severity.
  Autoimmunity Volume: 55 Page(s): 109 - 117
  03/01/2022 Authors: Linnemann RW; Yadav R; Zhang C; Sarr D; Rada B; Stecenko AA
• A Randomized Clinical Trial of Antimicrobial Duration for Cystic Fibrosis Pulmonary Exacerbation Treatment.
  Am J Respir Crit Care Med Volume: 204 Page(s): 1295 - 1305
  12/01/2021 Authors: Goss CH; Heltshe SL; West NE; Skalland M; Sanders DB; Jain R; Barto TL; Fogarty B; Marshall BC; VanDevanter DR
• Improving lung function in adolescents with CF by tracking annual rate of lung function decline.
  BMJ Open Qual Volume: 10
  08/01/2021 Authors: Schiff S; Starks M; Linnemann RW
• Long-term safety and efficacy of tezacaftor-ivacaftor in individuals with cystic fibrosis aged 12 years or older who are homozygous or heterozygous for Phe508del CFTR (EXTEND): an open-label extension study.
  Lancet Respir Med Volume: 9 Page(s): 733 - 746
  07/01/2021 Authors: Flume PA; Biner RF; Downey DG; Brown C; Jain M; Fischer R; De Boeck K; Sawicki GS; Chang P; Paz-Diaz H
• Trajectories of oral glucose tolerance testing in cystic fibrosis.
  Pediatr Pulmonol Volume: 56 Page(s): 901 - 909
  05/01/2021 Authors: Patel M; McCracken C; Daley T; Stecenko A; Linnemann R
• Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor for 24 Weeks or Longer in People with Cystic Fibrosis and One or More F508del Alleles: Interim Results of an Open-Label Phase 3 Clinical Trial.
  Am J Respir Crit Care Med Volume: 203 Page(s): 381 - 385
  02/01/2021 Authors: Griese M; Costa S; Linnemann RW; Mall MA; McKone EF; Polineni D; Quon BS; Ringshausen FC; Taylor-Cousar JL; Withers NJ
• Use of the NINJA (Nephrotoxic Injury Negated by Just-in-Time Action) Program to Identify Nephrotoxicity in Pediatric Patients with Cystic Fibrosis.
  J Pediatr Pharmacol Ther Volume: 26 Page(s): 379 - 383
  01/01/2021 Authors: Newton ES; Kurzen EA; Linnemann RW; Shin HS
• IgA autoantibodies directed against self DNA are elevated in cystic fibrosis and associated with more severe lung dysfunction.
  Autoimmunity Volume: 53 Page(s): 476 - 484
  12/01/2020 Authors: Yadav R; Linnemann RW; Kahlenberg JM; Bridges LS; Stecenko AA; Rada B
• Transition Planning for Chronic Illnesses in the Time of COVID-19.
  J Patient Exp Volume: 7 Page(s): 848 - 850
  12/01/2020 Authors: Hunt WR; Linnemann RW; Middour-Oxler B
• IPS-DERIVED AIRWAY CELL RESPONSE TO CFTR MODULATION: STUDY OF TRIPLE COMBINATION THERAPY IN CF PATIENTS WITHOUT AN APPROVED MODULATOR
  Volume: 55 Page(s): S207 - S207
  10/01/2020 Authors: Linnemann RW; Streby A; Rab A; Solomon GM; Hunter E; Hailemichael T; Driggers WC; Slaten K; Hathorne H; Hong JS
• Maternal Fish Consumption in Pregnancy Is Associated with a Bifidobacterium-Dominant Microbiome Profile in Infants.
  Curr Dev Nutr Volume: 4 Page(s): nzz133
  01/01/2020 Authors: Simione M; Harshman SG; Castro I; Linnemann R; Roche B; Ajami NJ; Petrosino JF; Raspini B; Portale S; Camargo CA
• Elexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele.
  N Engl J Med Volume: 381 Page(s): 1809 - 1819
  11/07/2019 Authors: Middleton PG; Mall MA; Devnek P; Lands LC; McKone EF; Polineni D; Ramsey BW; Taylor-Cousar JL; Tullis E; Vermeulen F
• AUTOANTIBODIES DIRECTED AGAINST SELF DNA ARE ELEVATED IN CYSTIC FIBROSIS
  Volume: 54 Page(s): S329 - S329
  10/01/2019 Authors: Yadav R; Linnemann RW; Kahlenberg JM; Stecenko A; Rada B
• TRAJECTORIES OF ORAL GLUCOSE TOLERANCE TESTING AND THE ASSOCIATION BETWEEN MILD DISTURBANCES IN GLUCOSE HOMEOSTASIS AND LUNG FUNCTION IN CF
  Volume: 54 Page(s): S221 - S222
  10/01/2019 Authors: Patel M; McCracken C; Stecenko A; Linnemann RW
• Effects of a primary palliative care intervention on quality of life and mental health in cystic fibrosis.
  Pediatr Pulmonol Volume: 54 Page(s): 984 - 992
  07/01/2019 Authors: Friedman D; Linnemann RW; Altstein LL; Georgiopoulos AM; Islam S; Bach K-T; St John A; Fracchia MS; Neuringer I; Lapey A
• Advance Care Planning Experiences and Preferences among People with Cystic Fibrosis.
  J Palliat Med Volume: 22 Page(s): 138 - 144
  02/01/2019 Authors: Linnemann RW; Friedman D; Altstein LL; Islam S; Bach K-T; Georgiopoulos AM; Moskowitz SM; Yonker LM
• VANCOMYCIN VERSUS LINEZOLID FOR TREATMENT OF MRSA PULMONARY EXACERBATIONS IN HOSPITALIZED PEDIATRIC CYSTIC FIBROSIS PATIENTS
  Volume: 53 Page(s): 296 - 297
  09/01/2018 Authors: Ward A; Kurzen E; Travers CD; Duval MA; Linnemann R
• IMPROVING LUNG FUNCTION IN CF ADOLESCENTS
  Volume: 53 Page(s): 380 - 380
  09/01/2018 Authors: Linnemann RW; Wei J; Starks M; Stecenko A
• The CF-CARES primary palliative care model: A CF-specific structured assessment of symptoms, distress, and coping.
  J Cyst Fibros Volume: 17 Page(s): 71 - 77
  01/01/2018 Authors: Friedman D; Linnemann RW; Altstein LL; Islam S; Bach K-T; Lamb C; Volpe J; Doolittle C; St John A; O'Malley PJ
• Nasal Airway Microbiota Profile and Severe Bronchiolitis in Infants: A Case-control Study.
  Pediatr Infect Dis J Volume: 36 Page(s): 1044 - 1051
  11/01/2017 Authors: Hasegawa K; Linnemann RW; Mansbach JM; Ajami NJ; Espinola JA; Petrosino JF; Piedra PA; Stevenson MD; Sullivan AF; Thompson AD
• QUALITY OF LIFE AND MENTAL HEALTH OUTCOMES OF THE CF-CARES PRIMARY PALLIATIVE CARE MODEL FOR CYSTIC FIBROSIS
  Volume: 52 Page(s): S502 - S502
  09/01/2017 Authors: Friedman D; Linnemann RW; Altstein L; Georgiopoulos A; Islam S; Bach K; St John A; Moskowitz SM; Yonker LM
• MENTAL HEALTH AND PULMONARY OUTCOMES IN CF ADOLESCENTS AND ADULTS
  Volume: 52 Page(s): S494 - S494
  09/01/2017 Authors: Linnemann RW; Blair SD; Hunt WR; Walker SD; Stecenko A
• ADVANCED CARE PLANNING IN CYSTIC FIBROSIS
  Volume: 52 Page(s): S493 - S494
  09/01/2017 Authors: Linnemann RW; Friedman D; Altstein L; Georgiopoulos A; Islam S; Bach K; St John A; Moskowitz SM; Yonker LM
• Sphingolipid metabolism potential in fecal microbiome and bronchiolitis in infants: a case-control study.
  BMC Res Notes Volume: 10 Page(s): 325
  07/26/2017 Authors: Hasegawa K; Stewart CJ; Mansbach JM; Linnemann RW; Ajami NJ; Petrosino JF; Camargo CA
• Household siblings and nasal and fecal microbiota in infants.
  Pediatr Int Volume: 59 Page(s): 473 - 481
  04/01/2017 Authors: Hasegawa K; Linnemann RW; Mansbach JM; Ajami NJ; Espinola JA; Fiechtner LG; Petrosino JF; Camargo CA
• Cohort Study of Severe Bronchiolitis during Infancy and Risk of Asthma by Age 5 Years.
  J Allergy Clin Immunol Pract Volume: 5 Page(s): 92 - 96
  01/01/2017 Authors: Balekian DS; Linnemann RW; Hasegawa K; Thadhani R; Camargo CA
• The Fecal Microbiota Profile and Bronchiolitis in Infants.
  Pediatrics Volume: 138
  07/01/2016 Authors: Hasegawa K; Linnemann RW; Mansbach JM; Ajami NJ; Espinola JA; Petrosino JF; Piedra PA; Stevenson MD; Sullivan AF; Thompson AD
• Cohort study of severe bronchiolitis during infancy and risk of asthma by age 5 years
  Volume: 37 Page(s): 344 - 344
  07/01/2016 Authors: Balekian DS; Linnemann RW; Hasegawa K; Thadhani R; Camargo CA
• Pre-birth cohort study of atopic dermatitis and severe bronchiolitis during infancy.
  Pediatr Allergy Immunol Volume: 27 Page(s): 413 - 418
  06/01/2016 Authors: Balekian DS; Linnemann RW; Castro VM; Perlis R; Thadhani R; Camargo CA
• Pre-Birth Cohort Study of Atopic Dermatitis and Severe Bronchiolitis during Infancy
  Volume: 137 Page(s): AB145 - AB145
  02/01/2016 Authors: Balekian DS; Linnemann RW; Castro VM; Perlis R; Thadhani R; Camargo C
• Development and evaluation of a palliative care curriculum for cystic fibrosis healthcare providers.
  J Cyst Fibros Volume: 15 Page(s): 90 - 95
  01/01/2016 Authors: Linnemann RW; O'Malley PJ; Friedman D; Georgiopoulos AM; Buxton D; Altstein LL; Sicilian L; Lapey A; Sawicki GS; Moskowitz SM
• Detection of respiratory syncytial virus and rhinovirus in healthy infants.
  BMC Res Notes Volume: 8 Page(s): 718
  11/25/2015 Authors: Hasegawa K; Linnemann RW; Avadhanula V; Mansbach JM; Piedra PA; Gern JE; Camargo CA
• An update on United States asthma centers: 2013.
  Ann Allergy Asthma Immunol Volume: 113 Page(s): 484 - 6.e1
  10/01/2014 Authors: Sullivan AF; Hasegawa K; Linnemann RW; Long AA; Teuber SS; Turner SJ; Massaro S; Camargo CA; MARC-36 Investigators
• DEVELOPMENT OF A CF-SPECIFIC PALLIATIVE CARE CURRICULUM AND ASSESSMENT OF CF PROVIDER COMFORT WITH PALLIATIVE CARE SKILLS
  Volume: 49 Page(s): 428 - 429
  09/01/2014 Authors: Linnemann RW; Buxton D; O'Malley PJ; Friedman D; Georgiopoulos AM; Sicilian L; Sawicki GS; Moskowitz SM
• Describing genetic variation and panel detection rates for a diverse cystic fibrosis center in Georgia
  Journal of Cystic Fibrosis
  Authors: Sanchez Russo R; Barr E; Linnemann R; Oliver K; truitt B